Feed / IRON

Disc Medicine, Inc.

IRON

Healthcare · 74.20 -2.9% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

Disc Medicine, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Company-2.9% todayVolume comparison unavailable
Market group0 of 37 activeBiotechnology · unavailable
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
  • R&D personnel-related costs increased $7.1M, including a $2.8M rise in stock-based compensation tied to equity awards.
  • SG&A personnel-related costs increased $8.7M contributing to an $11.4M total increase; includes $2.8M stock-based comp and $1.6M restructuring.

Invalidation: The isolated read changes if IRON's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • R&D personnel-related costs increased $7.1M, including a $2.8M rise in stock-based compensation tied to equity awards.
  • SG&A personnel-related costs increased $8.7M contributing to an $11.4M total increase; includes $2.8M stock-based comp and $1.6M restructuring.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods0
Price observations327
Usable filing statements70
Verified relationships3
Evidence supporting the case
  • Product pipeline and R&D has repeated favorable evidence across 5 filings.
Evidence challenging the case

No qualifying adverse evidence was identified; that is not proof there is no downside.

Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 10, 2026

74.20
6m+16.2%12m+23.0%24m

What management says matters

Persistent and emerging business drivers

Legal and regulatory exposuremixed · 5 filings
The Company was not subject to any material legal proceedings during the six months ended June 30, 2026 and 2025 and, to the best of its knowledge, no material legal proceedings are currently pending or threatened.
10-Q · Jul 30, 2026
Product pipeline and R&Dpositive · 5 filings
The increase of $18.8 million was primarily due to an increase of $13.1 million in personnel-related costs related to higher research and development headcount, including an increase of $6.0 million in stock-based 22 compensation driven by awards granted unde…
10-Q · Jul 30, 2026
Credit and interest ratesmixed · 4 filings
Other income (expense), net consists primarily of interest income from our cash, cash equivalents and marketable securities, partially offset by interest expense associated with our term loan.
10-Q · Jul 30, 2026
Restructuring and cost reductionspositive · 2 filings
The increase of $14.5 million was primarily due to an increase of $12.6 million in personnel-related costs due to increased selling, general and administrative headcount, including an increase of $5.1 million in stock-based compensation driven by awards grant…
10-Q · Jul 30, 2026

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Fewer than 4 annual revenue periods; too little history to scaffold scenarios.

Price action

How the market is pricing the story

74.20-2.9% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for IRON. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for IRON. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind IRON

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

HTGCHercules Capital, Inc.partnerNov 6, 2025

We may also pursue additional cash resources through public or private equity offerings, collaborations or additional draws under the Hercules Loan Agreement.

HTGCHercules Capital, Inc.lenderMay 5, 2026

Interest Expense Interest expense primarily consists of amortization of debt issuance costs and discount and interest expense under the Hercules Loan Agreement.

ABBVAbbVie Inc.partnerNov 6, 2025

We are party to license agreements with Roche, AbbVie and Mabwell and we may from time to time in the future be party to other license and collaboration agreements with third parties to advance our research or allow commercialization of current or future prod…

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

IRON is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for IRON; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.